Hydroxychloroquine is embroiled in yet more controversy
And so is the idea of peer review
ONCE PRAISED as a miracle cure for covid-19, an antimalarial drug called hydroxychloroquine has rarely been out of the headlines since the start of the pandemic. It was hoped it might find a new use as a therapy in patients who are unwell with the novel coronavirus. But in recent weeks a scientific picture has emerged of a treatment that does not appear to be helping patients at all, and might even be causing harm.
This article appeared in the Science & technology section of the print edition under the headline “Testing times”
More from Science & technology
Can you breathe stress away?
Scientists are only beginning to understand the links between the breath and the mind
The Economist’s science and technology internship
We invite applications for the 2025 Richard Casement internship
A better understanding of Huntington’s disease brings hope
Previous research seems to have misinterpreted what is going on
Is obesity a disease?
It wasn’t. But it is now
Volunteers with Down’s syndrome could help find Alzheimer’s drugs
Those with the syndrome have more of a protein implicated in dementia
Should you start lifting weights?
You’ll stay healthier for longer if you’re strong